Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Monoamine releasing agentLSD, psilocybin, mescaline +1 moreLSD, psilocybin, mescaline, DMT show less
5-MeO-AMT
5-methoxy-α-methyltryptamine
5-MeO-AMT (5-methoxy-α-methyltryptamine) — also known as Alpha-O — is a synthetic psychedelic of the tryptamine class. It is the α-methyl structural analog of 5-MeO-DMT, orally active and far longer-lasting.[1] It activates serotonin receptors and drives monoamine release, producing a combined psychedelic and stimulant effect.[2][3]
5-MeO-AMT (5-methoxy-α-methyltryptamine) — also known as Alpha-O — is a synthetic psychedelic of the tryptamine class. It is the α-methyl structural analog of 5-MeO-DMT, distinguished by oral activity and exceptional duration.[1] 5-MeO-AMT is a 5-HT₂A receptor agonist that also drives monoamine release, producing its effects through serotonergic disruption of sensory filtering combined with broad-spectrum stimulation.[2][3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Monoamine releasing agentLSD, psilocybin, mescaline +1 moreLSD, psilocybin, mescaline, DMT show less
First synthesized around 1958, its psychedelic properties were characterized by Shulgin and Nichols in 1978.[4] Around 2000, it emerged on research chemical markets as pressed tablets, sometimes misrepresented as LSD — a dangerous substitution, since the two compounds are active at entirely different doses.[5] It remains federally unscheduled in the United States after the DEA withdrew a proposed Schedule I placement in July 2022.[6]
Subjective effects include geometric visual patterns, physical stimulation, mood elevation, cognitive enhancement, and pronounced nausea.[7] The experience layers psychedelic perceptual shifts onto a persistent stimulant undercurrent — physically demanding, with a somatically heavy arc shaped substantially by dose and psychological context. Nausea, muscle tension, and anxious overstimulation are characteristic unsought effects.
5-MeO-AMT does not produce physical dependence, but the margin between active and dangerous doses is narrow.[8][9] Its serotonin activation and monoamine release create a dangerous overdose pattern — rapid heart rate, seizures, and dangerously elevated body temperature — and fatalities in polydrug contexts are documented.[8] No controlled human studies exist; what is known comes from self-experimentation, community data, and animal research.
History[edit]
Discovery
5-MeO-AMT was first synthesized around 1958.[4] Its psychedelic properties went undocumented until 1978, when Alexander Shulgin and David Nichols characterized the compound's effects.[4] Shulgin later included it in TiHKAL (1997) under the designation α,O-DMS, reporting an oral dose range of 2.5–4.5 mg and a duration of 12–18 hours.[1]
Market emergence and misidentification
5-MeO-AMT appeared on research chemical markets around 2000–2002 as pressed tablets sold as "Alpha-O".[5][4] It was sometimes misrepresented as LSD on blotter or in liquid — a dangerous substitution, since 5-MeO-AMT is active at milligram doses while LSD is active at microgram doses.[8] Users who received it believing it was AMT also faced overdose risk — AMT requires a much higher active dose (15–50 mg vs. 2.5–4.5 mg).[7][5]
Regulatory history
The DEA proposed placing 5-MeO-AMT in Schedule I in January 2022, citing reports of agitation, psychological distress, and death.[10] The agency withdrew the proposal six months later without publicly stating its reasons.[6] As of 2026, the compound remains federally unscheduled in the United States, though it is controlled in the United Kingdom (Class A), Australia (Schedule 9), and Sweden.
The name Alpha-O comes from the compound's structural features: the α-methyl group on the side chain and the O-methyl (methoxy) group at position 5 of the indole ring. Shulgin's designation α,O-DMS (alpha,O-dimethylserotonin) captures the same logic — two methyl additions to the serotonin molecule. The compound has a reputation in research chemical communities for its unusual combination of psychedelic and stimulant effects, a dual character that sets it apart from most tryptamines.
Chemistry[edit]
Structural class
5-MeO-AMT belongs to the substituted tryptamine family, sharing the same core scaffold as DMT, psilocin, and 5-MeO-DMT. The α-methyl group on its side chain resists the enzyme that would otherwise break it down quickly, enabling the compound to work when swallowed and to last 12–18 hours.[1]
Molecular properties
| Molecular formula | C₁₂H₁₆N₂O |
| Molecular weight | 204.27 g/mol |
The molecule is built on a bicyclic indole ring, with a methoxy group at position 5 and a 2-aminopropyl side chain at position 3.[11]
| Melting point | 216–218 °C |
| Solubility | Soluble in ethanol |
| Appearance | White to off-white powder (freebase); also distributed as pressed tablets and on blotter |
No published salt form or water solubility data for the freebase have been located.[8]
Pharmacology[edit]
Mechanism of action
5-MeO-AMT produces its psychedelic effects primarily by activating serotonin receptors. Animal studies confirm this: the compound produces a dose-dependent behavioral response in mice, and that response is fully blocked when serotonin receptors are inhibited.[9][12]
Unlike most serotonergic psychedelics, 5-MeO-AMT also forces the release of serotonin, dopamine, and norepinephrine — a stimulant-like action layered on top of its psychedelic one.[2][3] In animal studies it partially resembled LSD but did not cleanly match any classic psychedelic or stimulant, suggesting it occupies pharmacological territory between the two categories.[13]
Pharmacokinetics
No human pharmacokinetic studies have been published. The 12–18 hour oral duration reflects the α-methyl group's resistance to the enzyme that breaks down most tryptamines. Animal studies have identified complex metabolic byproducts in urine,[14] and the expected breakdown pathways include chemical changes to both the methoxy group and the indole ring.[15]
Neuroscience[edit]
Where it acts
5-MeO-AMT activates cortical circuits in the prefrontal cortex and disrupts the brain's sensory filtering systems — the same pathways affected by other serotonergic psychedelics.[3] Animal studies confirm it directly increases serotonin receptor gene expression in the prefrontal cortex.[9]
It also raises dopamine and serotonin levels across brain regions involved in reward, memory, and movement — including the nucleus accumbens, striatum, and hippocampus.[16] This broader engagement distinguishes it from psilocin, which acts more selectively on serotonin pathways.
Why it matters
Despite releasing dopamine in reward-relevant brain regions, 5-MeO-AMT does not produce reinforcing behavior in animal models — no preference for environments where it was given, no self-administration.[9][16] The concurrent serotonin receptor activation appears to suppress the reinforcing effect of dopamine — a pattern seen with serotonergic psychedelics generally.
- Does the 12–18-hour duration produce qualitatively different neural changes than shorter-acting psychedelics? Extended serotonin receptor activation could yield either deeper or more disorganized effects on cortical plasticity. inferred
- What is the functional contribution of dopamine and norepinephrine release to the subjective experience? The mixed mechanism is uncommon among psychedelics and its neural consequences are poorly understood.
- How does genetic variation in drug-metabolizing enzymes affect brain exposure and adverse event risk?[15]
Subjective Effects[edit]
The 5-MeO-AMT experience is defined by a dual pharmacological identity: serotonergic psychedelia layered over stimulant activity. At lower doses the stimulant character leads — physical energy, sharpened cognition, mild perceptual brightening. As dose increases, overtly psychedelic features emerge: visual distortion, conceptual fluidity, and altered sense of self. The extended arc means physical stamina matters as much as psychological preparation.
Compared to LSD, 5-MeO-AMT is more physically stimulating and somatically demanding, with heavier gastrointestinal effects. Compared to αMT, it is roughly an order of magnitude more potent, more overtly psychedelic in character, and carries a narrower margin between active and dangerous doses.
First synthesized around 1958, 5-MeO-AMT was characterized as a psychedelic by Shulgin and Nichols in 1978.[4] It appeared on research chemical markets as pressed tablets around 2000–2002, sometimes misrepresented as LSD — a substitution that created serious overdose risk due to the compound's narrow safety margin.[5] It remains federally unscheduled in the United States after the DEA withdrew a proposed Schedule I placement in July 2022.[6]
Subjective effects include geometric visual patterns, cognitive enhancement, physical stimulation, and pronounced gastrointestinal distress.[7] The experience combines psychedelic perceptual shifts with a persistent stimulant undercurrent — a physically demanding, somatically heavy arc shaped substantially by dose, route, and psychological context. Nausea, muscle tension, and anxious overstimulation are characteristic unsought effects.
5-MeO-AMT produces no physical dependence, but its therapeutic index is narrow — overdose symptoms appear at doses only a few times above the common range.[8][9] The compound's combined serotonin agonism and monoamine release produce a sympathomimetic toxidrome at excess doses, and fatalities in polydrug contexts are documented.[8] No controlled human studies have been conducted; the entire evidence base rests on self-experimentation, community data, and preclinical research.
History[edit]
Discovery
5-MeO-AMT was first synthesized in the late 1950s, with some sources citing approximately 1958.[4] Its psychoactive properties remained undocumented until 1978, when Alexander Shulgin and David Nichols published the first characterization of its psychedelic effects in humans.[4] Shulgin later included the compound in TiHKAL (1997) under the designation α,O-DMS, reporting an oral dose range of 2.5–4.5 mg and a duration of 12–18 hours.[1]
Market emergence and misidentification
5-MeO-AMT appeared on research chemical markets around 2000–2002 as pressed tablets sold under the name "Alpha-O," coinciding with a major disruption of global LSD supply.[5][4] The compound was sometimes misrepresented as LSD on blotter or in liquid form — a dangerous substitution, since 5-MeO-AMT is active at milligram doses with a narrow safety margin, while LSD is active at microgram doses with a wide one.[8] Further confusion arose from its similarity to AMT, which has a much higher active dose range (15–50 mg); a user receiving 5-MeO-AMT believing it to be AMT risked consuming a drastically excessive amount.[7][5]
Regulatory history
The DEA proposed placing 5-MeO-AMT in Schedule I in January 2022, citing reports of agitation, psychological distress, and death.[10] In an unusual reversal, the agency withdrew the proposal six months later without publicly detailing its reasons.[6] As of 2026, 5-MeO-AMT remains federally unscheduled in the United States, though it is controlled in the United Kingdom (Class A), Australia (Schedule 9), and Sweden.
The name Alpha-O derives from the compound's structural features: the α-methyl group on the side chain and the O-methyl (methoxy) group at the 5-position of the indole ring. Shulgin's designation α,O-DMS (alpha,O-dimethylserotonin) captures the same logic — two methyl additions to the serotonin molecule. The compound's reputation in research chemical communities centers on its unusual combination of psychedelic and stimulant effects, a dual character that distinguishes it from most tryptamines and has made it a subject of particular interest and caution.
Chemistry[edit]
Structural class
5-MeO-AMT belongs to the substituted tryptamine family, sharing the indole scaffold common to serotonin, DMT, psilocin, and 5-MeO-DMT. The compound can be understood as the α-methyl structural analog of 5-MeO-DMT or the 5-methoxy analogue of α-methyltryptamine. The α-methyl group on the ethylamine side chain — the same modification that distinguishes amphetamine from phenylethylamine — confers resistance to monoamine oxidase degradation, enabling oral activity and contributing to the compound's extended duration.[1]
Molecular properties
| Molecular formula | C₁₂H₁₆N₂O |
| Molecular weight | 204.27 g/mol |
The molecule consists of a bicyclic indole ring system with a methoxy group at position 5 and a 2-aminopropyl side chain at position 3.[11]
Stereochemistry
The α-methyl group creates a chirality centre, and 5-MeO-AMT exists as (R)- and (S)-enantiomers. No published data characterize the psychoactive potency or receptor selectivity of individual enantiomers. Research and community use is typically racemic mixture. citation needed
Physical properties
| Melting point | 216–218 °C |
| Solubility | Soluble in ethanol |
| Appearance | White to off-white powder (freebase); also distributed as pressed tablets and on blotter |
No published characterization of salt forms or water solubility data for the freebase was located.[8]
Pharmacology[edit]
Mechanism of action
5-MeO-AMT produces its psychedelic effects primarily through activation of the 5-HT₂A receptor. In rodent studies, the compound elicits dose-dependent head-twitch responses — the standard proxy for hallucinogenic activity — and this response is fully blocked by selective 5-HT₂A antagonists, confirming 5-HT₂A as the primary mediator.[9][12]
What sets 5-MeO-AMT apart from most serotonergic psychedelics is its additional action on monoamine transporters. The compound inhibits reuptake and induces release of serotonin, dopamine, and norepinephrine — a mixed inhibitor/releaser profile similar to αMT but uncommon among psychedelics.[2][3] This dual identity underlies the compound's stimulant-like qualities alongside its psychedelic effects.
In drug discrimination studies, 5-MeO-AMT produced partial substitution for LSD but did not fully substitute for DMT, DOM, LSD, cocaine, or methamphetamine.[13] The compound occupies pharmacological space between classical psychedelics and monoamine releasers without cleanly fitting either category.
Pharmacokinetics
No controlled pharmacokinetic studies have been published in humans. Key parameters — time to peak concentration, oral bioavailability, plasma half-life, and protein binding — remain uncharacterized.
The prolonged duration of action (12–18 hours orally) is consistent with the α-methyl group's resistance to monoamine oxidase degradation, which slows metabolism relative to non-α-methylated tryptamines like 5-MeO-DMT. Rat studies have confirmed a complex urinary metabolite profile,[14] and by analogy with structurally related compounds, the expected metabolic pathways include O-demethylation and aromatic hydroxylation.[15]
Monoamine oxidase A is the expected primary catabolic enzyme. This is the mechanistic basis for the critical interaction with MAO inhibitors: blocking this pathway would dramatically increase systemic exposure and prolong an already extended duration.
Neuroscience[edit]
Where it acts
As a potent serotonin 2A receptor agonist, 5-MeO-AMT is expected to activate the same cortical circuits disrupted by other serotonergic psychedelics: layer V pyramidal neurons in the prefrontal cortex, thalamocortical gating systems, and the default mode network.[3] Preclinical studies confirm direct molecular engagement — the compound increases 5-HT₂A gene expression in the prefrontal cortex and activates downstream signalling cascades associated with neuroplasticity.[9]
Neurochemistry studies in rats show that 5-MeO-AMT simultaneously affects dopamine and serotonin levels across the prefrontal cortex, nucleus accumbens, striatum, and hippocampus.[16] This broader engagement pattern — spanning reward, executive, motor, and memory circuits — distinguishes it from pure serotonergic psychedelics like psilocin.
Why it matters
5-MeO-AMT activates intracellular signalling pathways that overlap with those implicated in psychedelic-induced structural neuroplasticity — the growth of new neural connections.[9] Whether the compound actually promotes these changes at relevant concentrations has not been tested directly.
Despite measurable dopamine release in reward-relevant brain regions, 5-MeO-AMT does not produce self-administration, conditioned place preference, or locomotor sensitization in rodents.[9][16] This dissociation — dopamine release without behavioural reinforcement — is consistent with the broader pattern for serotonergic psychedelics, where concurrent 5-HT₂A activation appears to attenuate the rewarding properties of dopamine.
- Does the 12–18-hour duration produce qualitatively different neural changes than shorter-acting psychedelics? Extended 5-HT₂A activation could yield either deeper or more disorganized effects on cortical plasticity. inferred
- What is the functional contribution of dopamine and norepinephrine release to the subjective experience? The mixed mechanism is uncommon among psychedelics and its neural consequences are poorly understood.
- How does genetic variation in drug-metabolizing enzymes affect brain exposure and adverse event risk?[15]
Subjective Effects[edit]
The 5-MeO-AMT experience is defined by a dual pharmacological identity: serotonergic psychedelia layered atop monoamine-driven stimulation. At lower doses, the stimulant character predominates — physical energy, cognitive sharpening, mild perceptual enhancement. As dose increases, overtly psychedelic features emerge: visual distortion, conceptual fluidity, and altered sense of self. Set and setting modulate the experience more than with most psychedelics, partly because the extended duration makes environmental stability and psychological preparation unusually consequential.
Relative to LSD, 5-MeO-AMT is more physically stimulating and somatically demanding, with heavier gastrointestinal effects. Compared to αMT, it is approximately an order of magnitude more potent and carries a more overtly psychedelic character, with a narrower margin between active and dangerous doses.
Effect Grid
The full psychedelic-stimulant experience unfolds. Color enhancement and brightness alteration transform the visual field; geometry and environmental patterning emerge; visual drifting and breathing of surfaces become apparent. Cognitive euphoria, thought acceleration, conceptual thinking, and creativity enhancement are prominent. Sociability and communication enhancement are frequently reported.
The body load is substantial. Nausea and vomiting are near-universal during the come-up, often accompanied by diarrhea and muscle tension. Temperature dysregulation produces alternating chills and warmth. Stimulation and wakefulness are pronounced — sleep is impossible for 8+ hours. Pupil dilation is visible. Physical fatigue accumulates during the offset.
Total duration spans 12-18 hours including aftereffects. This is a full-day commitment. Set aside responsibilities, ensure a stable environment, and have water and comfort items accessible. Do not plan to drive or operate machinery for at least 18 hours.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Light sensitivity · Sound sensitivity · Music enhancement · Holotropic state · Sleep-transition hallucinations · Visual morphing · Color alteration · Brightness alteration · Visual haze / noise · Tracers · After-images · Visual melting · Auditory distortion · Auditory enhancement · Depth perception distortion · Perspective distortion · Spatial disorientation · Environmental patterning · Touch enhancement · Synesthesia · Symmetrical texture repetition · Proprioceptive distortion · Vestibular distortion · Peripheral vision distortion · Peripheral misidentification · Auditory misinterpretation · Visual diffraction · Visual processing acceleration · Tinnitus · Dreaming enhancement · Visual acuity enhancement · Visual magnification · Flashbacks · External hallucinations · Internal hallucinations · Object transformations · Object activation · Visual recursion · Auditory hallucinations · Perspective hallucinations · Environmental orbism / cubism · Visual flipping · Persisting hallucinations · Shadow people · Visual scenery slicing
Sleep-transition hallucinations · Visual morphing · Color alteration · Brightness alteration · Visual haze / noise · Tracers · After-images · Visual melting · Auditory distortion · Auditory enhancement · Depth perception distortion · Perspective distortion · Spatial disorientation · Environmental patterning · Touch enhancement · Synesthesia · Symmetrical texture repetition · Proprioceptive distortion · Vestibular distortion · Peripheral vision distortion · Peripheral misidentification · Auditory misinterpretation · Visual diffraction · Visual processing acceleration · Tinnitus · Dreaming enhancement · Visual acuity enhancement · Visual magnification · Flashbacks · External hallucinations · Internal hallucinations · Object transformations · Object activation · Visual recursion · Auditory hallucinations · Perspective hallucinations · Environmental orbism / cubism · Visual flipping · Persisting hallucinations · Shadow people · Visual scenery slicing
Body scan awareness · Nausea · Muscle tension · Insomnia · Restlessness · Body high · Trembling · Excessive sweating · Dry mouth · Spontaneous body sensations · Heart rate perception changes · Physical fatigue · Appetite suppression · Dizziness · Tingling / electric sensations · Vibrations / buzzing · Dehydration sensation · Tactile euphoria · Vomiting · Bruxism · Headache · Bodily pressures · Body schema distortion · Breathing alteration · Involuntary body movements · Bodily lightness · Nystagmus (eye wobbles) · Sexual arousal enhancement · Laughter fits · Diarrhea · Respiratory stimulation · Bodily heaviness · Watery eyes · Bodily dissociation · Tactile hallucination
Restlessness · Body high · Trembling · Excessive sweating · Dry mouth · Spontaneous body sensations · Heart rate perception changes · Physical fatigue · Appetite suppression · Dizziness · Tingling / electric sensations · Vibrations / buzzing · Dehydration sensation · Tactile euphoria · Vomiting · Bruxism · Headache · Bodily pressures · Body schema distortion · Breathing alteration · Involuntary body movements · Bodily lightness · Nystagmus (eye wobbles) · Sexual arousal enhancement · Laughter fits · Diarrhea · Respiratory stimulation · Bodily heaviness · Watery eyes · Bodily dissociation · Tactile hallucination
Conceptual thinking · Thought connectivity · Introspection enhancement · Pattern recognition enhancement · Multiple thought streams · Cognitive flexibility · Memory fragmentation · Cognitive impairment · Immersion enhancement · Openness enhancement · Novelty enhancement · Aesthetic enhancement · Cognitive fatigue · Cognitive dysphoria · Creativity enhancement · Memory suppression · Thought disorganization · Thought loops · Focus suppression · Synchronicity · Increased nature relatedness · Analysis enhancement · Humor enhancement · Motivation enhancement · Analysis suppression · Information processing suppression · Memory replays · Compulsive redosing urge · Focus enhancement · Information processing enhancement · Language enhancement · Delirium · Delusions · Amnesia
Pattern recognition enhancement · Multiple thought streams · Cognitive flexibility · Memory fragmentation · Cognitive impairment · Immersion enhancement · Openness enhancement · Novelty enhancement · Aesthetic enhancement · Cognitive fatigue · Cognitive dysphoria · Creativity enhancement · Memory suppression · Thought disorganization · Thought loops · Focus suppression · Synchronicity · Increased nature relatedness · Analysis enhancement · Humor enhancement · Motivation enhancement · Analysis suppression · Information processing suppression · Memory replays · Focus enhancement · Information processing enhancement · Language enhancement · Delirium · Delusions · Amnesia
Empathy enhancement · Emotional lability · Simultaneous emotions · Irritability · Dysphoria · Catharsis · Anhedonia · Anxiety suppression · Mania
Irritability · Dysphoria · Catharsis · Anhedonia · Anxiety suppression
Emotional susceptibility · Sociability enhancement · Trust enhancement · Social connection · Communication enhancement · Craving · Flow state · Social disconnection · Ego inflation · Automaticity · Sociability suppression · Communication suppression · Boundary dissolution · Ego dissolution · Identity alteration · Cognitive disconnection · Telepathic feelings
Communication enhancement · Craving · Flow state · Social disconnection · Ego inflation · Automaticity · Sociability suppression · Communication suppression · Boundary dissolution · Ego dissolution · Identity alteration · Cognitive disconnection · Telepathic feelings
Time cessation
Entity contact · Non-dual awareness · Death-rebirth sequence · Voidness · Transpersonal memory access · Near-death experience · Cessation
Transpersonal memory access · Near-death experience · Cessation
Mindfulness enhancement · Recursive awareness
Timeline
Gastrointestinal discomfort and restlessness emerge as the first signals. Mild anxiety and stomach awareness develop gradually. No perceptual changes yet.
Stimulation rises steadily alongside emerging color enhancement and brightness alteration. Nausea peaks during this phase; vomiting is common. Mood elevation and thought acceleration begin.
Full psychedelic-stimulant experience: geometry, environmental patterning, cognitive euphoria, sociability enhancement, and pronounced body load. Visual drifting, conceptual thinking, and emotional enhancement are prominent. GI distress may persist.
Visual and cognitive effects gradually diminish. Residual stimulation and wakefulness persist. Physical fatigue emerges but sleep remains difficult.
Residual stimulation fades into physical fatigue and possible headache. Reflective or contemplative mood. Appetite slowly returns.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Low
- Cross-tol.
- LSD · psilo · mesc
Toxicity
Acute toxicity
No published lethal dose data exist for 5-MeO-AMT in any species.[12] safety citation needed
The margin between active and dangerous doses is narrow. Shulgin reported an active oral dose range of 2.5–4.5 mg;[1] overdose symptoms have been reported at doses as low as 20 mg — roughly 4–10 times the common range.[7][8] This is substantially narrower than LSD or psilocybin.
An overdose produces a stimulant toxicity pattern: rapid heart rate, high blood pressure, seizures, dangerously elevated body temperature, and cardiac rhythm disturbances.[17]
Fatalities
At least two deaths have been documented in secondary sources. One 2004 fatality involved 5-MeO-AMT combined with alcohol and bupropion; the relative contribution of each substance was not determined.[8] The U.S. Department of Health and Human Services cited reports of agitation, confusion, psychological distress, and death in its 2022 scheduling evaluation.[10] safety citation needed
Multiple hospitalizations have resulted from misidentification as αMT or LSD. A user consuming 15–50 mg thinking it was AMT would receive 3–20 times the upper active dose range.[7][5]
Cardiovascular risk
5-MeO-AMT strongly activates a serotonin receptor subtype associated with abnormal tissue growth in heart valve cells.[3] Sustained activation causes valve cells to proliferate abnormally, which can lead to structural heart damage.[18][19] No clinical cases of 5-MeO-AMT-induced valve disease have been reported, most likely because the compound is rarely used repeatedly. This risk is relevant for any pattern of repeated use.
Psychological risks
High doses can produce panic, severe anxiety, confusion, and terrifying hallucinations.[5] The extended duration means adverse psychological experiences persist far longer than with shorter-acting psychedelics, with limited options beyond supportive care and sedation.
A personal or family history of psychotic spectrum conditions is a risk factor for psychedelic-triggered psychosis — a concern across all compounds that activate serotonin receptors.[7] No incidence data specific to 5-MeO-AMT have been published.
Tolerance and dependence
Tolerance builds with repeated use. In mice, seven days of repeated administration reduced behavioral effects while increasing serotonin receptor gene expression in the prefrontal cortex — a compensatory shift consistent with receptor desensitization.[9] Cross-tolerance with LSD, psilocybin, and mescaline is expected, since all operate through the same serotonin receptor.[20]
5-MeO-AMT does not produce physical dependence. Animal studies found no reinforcing behavior — no self-administration, no preference for environments where it was given.[9] No human data on dependence or withdrawal exist.
Drug Interactions
No published drug interaction studies exist for 5-MeO-AMT. All interaction guidance relies on pharmacological reasoning.
MAO inhibitors
Combining 5-MeO-AMT with monoamine oxidase inhibitors — including prescription MAOIs (phenelzine, tranylcypromine, moclobemide) and plant-based sources (ayahuasca, Syrian rue) — would dramatically slow its clearance, amplifying both intensity and duration.[7] This creates extreme risk of serotonin syndrome — a potentially fatal condition involving dangerously elevated body temperature, muscle rigidity, and cardiovascular collapse.
Serotonin reuptake inhibitors
SSRIs and SNRIs raise serotonin levels by blocking reuptake. Combining them with 5-MeO-AMT adds to the serotonin load and increases the risk of serotonin syndrome.[21] Chronic SSRI use may also blunt the psychedelic effect via downregulation, potentially encouraging dose escalation and increasing toxicity risk.
Bupropion
Bupropion was involved in the documented 2004 fatality alongside alcohol.[8] It lowers seizure threshold and may increase 5-MeO-AMT blood levels by inhibiting metabolic enzymes. The combination carries both seizure and serotonin syndrome risk.
Stimulants
Combining 5-MeO-AMT with stimulants — amphetamines, MDMA, cocaine — adds to the monoamine load from both sources. This can produce dangerous blood pressure elevation, rapid heart rate, and dangerously elevated body temperature.
Lithium
Lithium combined with serotonergic psychedelics is associated with unpredictable potentiation and increased seizure risk. No specific data exist for this combination. inferred
Contraindications
8 knownThe following contraindications are based on pharmacological mechanism and class-level evidence. No substance-specific contraindication studies have been published.
Absolute contraindications:
- Concurrent MAOI use — risk of fatal serotonin syndrome[7]
- Seizure disorders — the compound lowers seizure threshold at excessive doses[7][17]
- Heart rhythm disorders or structural heart disease — combined stimulant effects and potent serotonin receptor activation create dual cardiovascular risk[3]
Relative contraindications:
- Personal or family history of psychotic spectrum disorders — risk of psychedelic-triggered psychosis[7]
- Concurrent SSRI or SNRI use — serotonin syndrome risk[21]
- Concurrent lithium use — unpredictable potentiation and seizure risk inferred
- Liver impairment — expected impairment of metabolism could increase blood levels inferred
- Pregnancy and lactation — no reproductive toxicity data exist; contraindicated by precautionary principle
Harm Reduction[edit]
Forms & Identification
5-MeO-AMT is a white to off-white powder that cannot be visually distinguished from αMT, 5-MeO-DMT, or dozens of other tryptamines. Reagent testing can narrow identification but cannot confirm purity or precise composition.
Laboratory analysis through an energy-controlled substance checking service or mail-in testing provides the highest confidence in identity and dose accuracy. This matters especially for a compound active at single-digit milligram doses. When distributed on blotter or as tablets, the risk of substitution or mislabeling increases; the compound has historically been misrepresented as LSD.
Guidelines
- Test before use. Reagent testing narrows identification; laboratory analysis confirms it. Given the history of misidentification with this compound, testing is not optional.
- Weigh precisely. A milligram-capable scale (±1 mg) is essential. The difference between an active and a dangerous dose is measured in milligrams. Never estimate by eye.
- Start low. First-time use should begin at the lowest reported active dose. Wait a minimum of 2 hours before assessing whether effects have fully emerged. The slow onset makes premature redosing a serious risk.
- Do not redose. The long onset and extended duration create a strong temptation to take more before the first dose has peaked. This is the most common pathway to overdose with this compound.
- Clear the schedule. The experience will occupy most of a waking day at minimum, with residual effects potentially extending into the following day.
- Eat lightly beforehand. A light meal 2–3 hours before ingestion may reduce nausea. An empty stomach increases both nausea severity and rate of absorption.
- Stay hydrated. The stimulant component increases fluid loss. Sip water throughout the experience.
Set & Setting
The extended duration makes environmental planning more consequential than with shorter-acting psychedelics. A full day without obligations, a familiar and comfortable space, and access to food and water are essential. The compound's stimulant properties can mask dehydration and overheating — temperature regulation matters.
A trusted, sober companion is strongly recommended for the entire experience. The extended timeframe means the sitter may need to rotate or rest; plan accordingly. Significant nausea is common during onset — a comfortable place to sit or lie down near a bathroom is practical.
Aftercare & integration. The extended duration means physical recovery matters as much as psychological processing. Sleep may be difficult for several hours after primary effects subside — a dark, quiet environment helps. Eat a substantial meal when appetite returns, and continue hydrating.
The dual psychedelic and stimulant character can leave cognitive openness alongside physical depletion. Journaling or discussing the experience within 48 hours, while memories remain vivid, supports integration. If disturbing content emerged, speaking with a psychedelic-informed therapist is recommended rather than processing alone. Allow at least one full day of low-demand activity before returning to obligations.
Recovery & Support
5-MeO-AMT has low abuse liability and is not associated with compulsive use patterns. If use has become a pattern driven by avoidance, escapism, or compulsion rather than intentional exploration, this signals a relationship with the substance worth examining honestly.
Psychedelic-informed therapists, peer support communities, and integration circles can provide context and perspective. The Fireside Project (62-FIRESIDE / 623-473-7433) offers free peer support for people processing difficult psychedelic experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
Not every difficult moment requires medical intervention, but certain signs do:
- Seizures or convulsions
- Chest pain or irregular heartbeat
- Body temperature that can be felt through clothing (dangerously elevated)
- Loss of consciousness or inability to respond
- Severe confusion with self-harm risk
- Rigid muscles with high fever (possible serotonin syndrome — a potentially life-threatening overheating response)
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present.
- 2. Place the person in the recovery position if unconscious but breathing.
- 3. Do not attempt to restrain someone having a seizure — clear the area of hard objects and protect the head.
- 4. Remove excess clothing and apply cool (not cold) water if body temperature is elevated.
- 5. Do not induce vomiting.
- 6. Stay with the person until help arrives.
What to tell the dispatcher:
State the substance name (5-MeO-AMT), approximate dose if known, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency — calling for help is always the right decision.
Legal Status[edit]
5-MeO-AMT occupies an unusual legal position among serotonergic tryptamines. It remains federally unscheduled in the United States — a status preserved when the DEA withdrew a proposed Schedule I placement in July 2022.[6] The closely related αMT and 5-MeO-DMT are both Schedule I. In the United Kingdom and Australia, the compound is controlled under broad tryptamine scheduling provisions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (Federal) | Unscheduled | DEA proposed Schedule I placement January 14, 2022;[10] withdrawn July 27, 2022.[6] May be prosecutable under the Federal Analogue Act as an analogue of AMT or 5-MeO-DMT if intended for human consumption. |
| Florida (USA) | Schedule I | State-level scheduling; specifically listed. |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled from January 7, 2015 via updated generic tryptamine definition following ACMD recommendation. |
| Australia | Schedule 9 (Prohibited Substance) | Listed under the Poisons Standard.[8] |
| Sweden | Controlled (health hazard) | Classified under SFS 2004:696, Act on Prohibition of Certain Goods Dangerous to Health, from October 1, 2004. |
| Canada | Not specifically scheduled | Not explicitly listed in the Controlled Drugs and Substances Act. Potential analogue arguments may apply. |
Legal status changes frequently and varies by jurisdiction. The information above reflects status as of 2026 and is not legal advice. Verify current legislation before any activity involving this substance.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Low
- Cross-tol.
- LSD · psilo · mesc
Toxicity
Acute toxicity
No published LD₅₀ data exist for 5-MeO-AMT in any species.[12] safety citation needed
The compound has a narrow margin between active and dangerous doses. Shulgin reported an active oral dose range of 2.5–4.5 mg,[1] with overdose symptoms reported at doses as low as 20 mg — roughly 4–10 times the common range.[7][8] This is substantially narrower than LSD or psilocybin.
Overdose presents as a sympathomimetic toxidrome: rapid heart rate, high blood pressure, seizures, dangerously elevated body temperature, and cardiac rhythm disturbances.[17]
Fatalities
At least two deaths involving 5-MeO-AMT have been documented in secondary sources. One 2004 fatality involved the compound in combination with alcohol and bupropion; the relative contribution of each substance was not determined.[8] The U.S. Department of Health and Human Services cited reports of agitation, confusion, psychological distress, and death in its 2022 evaluation supporting the DEA's proposed scheduling.[10] safety citation needed
Multiple hospitalizations have resulted from misidentification of 5-MeO-AMT as αMT or LSD. A user consuming 15–50 mg believing the substance to be AMT would receive 3–20 times the upper active dose range.[7][5]
Cardiovascular risk
5-MeO-AMT is a potent activator of the serotonin₂B receptor.[3] Sustained 5-HT₂B activation is mechanistically linked to heart valve damage through abnormal tissue growth in valve cells.[18][19] No clinical cases of 5-MeO-AMT-induced valve disease have been reported, most likely because the compound is rarely used chronically. This risk should be considered for any pattern of repeated use.
Psychological risks
5-MeO-AMT can precipitate panic reactions, severe anxiety, confusion, and terrifying hallucinations — the latter specifically noted at higher doses.[5] The compound's extended duration means adverse psychological experiences persist far longer than with shorter-acting psychedelics, with limited options for intervention beyond supportive care and benzodiazepine sedation.
No data on HPPD incidence specific to 5-MeO-AMT have been published. Family history of psychotic spectrum disorders constitutes a risk factor for psychedelic-triggered psychosis — a class-level concern for all serotonin 2A receptor agonists.[7]
Tolerance and dependence
Tolerance develops through downregulation. Repeated administration over 7 days in mice reduced the head-twitch response while increasing 5-HT₂A gene expression in the prefrontal cortex — a compensatory transcriptional change consistent with receptor desensitization.[9] Cross-tolerance with other 5-HT₂A psychedelics (LSD, psilocybin, mescaline) is expected based on this shared mechanism.[20]
5-MeO-AMT does not produce physical dependence. Rodent studies found no conditioned place preference and no self-administration, indicating low reinforcement potential.[9] No human data on dependence, withdrawal, or addiction exist.
Drug Interactions
No published drug-drug interaction studies exist for 5-MeO-AMT. All interaction data relies on pharmacological extrapolation.
MAO inhibitors
The most dangerous combination. As a tryptamine primarily broken down by MAO-A, co-administration with monoamine oxidase inhibitors — including pharmaceutical MAOIs (phenelzine, tranylcypromine, moclobemide) and plant-based sources (ayahuasca, Syrian rue) — would dramatically reduce clearance, potentiating both intensity and duration and creating extreme risk of serotonin syndrome.[7] Serotonin syndrome is a potentially fatal condition involving dangerously elevated body temperature, muscle rigidity, and cardiovascular instability.
Serotonin reuptake inhibitors
SSRIs and SNRIs raise serotonin syndrome risk through additive serotonergic activity.[21] Chronic SSRI use may also blunt psychedelic effects via receptor downregulation, potentially encouraging dose escalation and increasing toxicity risk.
Bupropion
Documented in a polydrug fatality case (2004, with concurrent alcohol).[8] Bupropion lowers seizure threshold and may increase 5-MeO-AMT blood levels through enzyme inhibition. The combination carries both seizure and serotonergic risk.
Stimulants
Co-administration with stimulants (amphetamines, MDMA, cocaine) carries additive cardiovascular risk from combined monoamine activity, potentially producing dangerous blood pressure elevation, rapid heart rate, and dangerously elevated body temperature.
Lithium
Lithium with serotonergic psychedelics is associated with unpredictable potentiation and increased seizure risk. No specific data exist for this combination. inferred
Contraindications
8 knownThe following contraindications are based on pharmacological mechanism and class-level evidence. No substance-specific contraindication studies have been published.
Absolute contraindications:
- Concurrent MAOI use — risk of fatal serotonin syndrome[7]
- Seizure disorders — the compound lowers seizure threshold at excessive doses[7][17]
- Heart rhythm disorders or structural heart disease — combined sympathomimetic effects and potent 5-HT₂B activation create dual cardiovascular risk[3]
Relative contraindications:
- Personal or family history of psychotic spectrum disorders — risk of psychedelic-triggered psychosis[7]
- Concurrent SSRI or SNRI use — serotonin syndrome risk[21]
- Concurrent lithium use — unpredictable potentiation and seizure risk inferred
- Liver impairment — expected impairment of metabolism could increase blood levels inferred
- Pregnancy and lactation — no reproductive toxicity data exist; contraindicated by precautionary principle
Harm Reduction[edit]
Forms & Identification
5-MeO-AMT's primary identification challenge is distinguishing it from visually identical compounds with very different dose ranges. As a white to off-white powder, it cannot be told apart from αMT, 5-MeO-DMT, or dozens of other tryptamines by appearance alone. Reagent testing can narrow identification but cannot confirm purity or precise composition.
Laboratory analysis — through energy-controlled substance checking services or mail-in testing — provides the highest confidence in identity and dose accuracy. This is particularly important for a compound active at single-digit milligram doses. When distributed on blotter or as tablets, the risk of substitution or mislabeling increases; the compound has historically been misrepresented as LSD.
Guidelines
- Test before use. Reagent testing narrows identification; laboratory analysis confirms it. Given the history of misidentification with this compound, testing is not optional.
- Weigh precisely. A milligram-capable scale (±1 mg) is essential. The difference between an active and a dangerous dose is measured in milligrams. Never estimate by eye.
- Start low. First-time users should begin at the lowest reported active dose and wait a minimum of 2 hours before assessing whether effects have fully emerged. The slow onset makes premature redosing a serious risk.
- Do not redose. The long onset and extended duration create a strong temptation to take more before the first dose has peaked. This is the most common pathway to overdose with this compound.
- Clear your schedule. The experience will occupy most of a waking day at minimum, with residual effects potentially extending into the following day.
- Eat lightly beforehand. A light meal 2–3 hours before ingestion may reduce nausea. An empty stomach increases both nausea severity and rate of absorption.
- Stay hydrated. The stimulant component increases fluid loss. Sip water throughout the experience.
Set & Setting
The extended duration makes environmental planning more consequential than with shorter-acting psychedelics. A full day without obligations, a familiar and comfortable space, and access to food and water are essential. The compound's stimulant properties can mask dehydration and overheating — temperature regulation matters.
A trusted, sober companion is strongly recommended for the entire experience. The extended timeframe means the sitter may need to rotate or rest; plan accordingly. Significant nausea is common during onset — having a comfortable place to sit or lie down near a bathroom is practical.
Aftercare & integration. The extended duration means physical recovery matters as much as psychological processing. Sleep may be difficult for several hours after the primary effects subside — a dark, quiet environment can help. Eat a substantial meal when appetite returns, and continue hydrating.
The experience's dual psychedelic and stimulant character can leave a mixed psychological residue: cognitive openness paired with physical depletion. Journaling or discussing the experience within the first 48 hours, while memories remain vivid, supports integration. If disturbing content emerged, speaking with a psychedelic-informed therapist is recommended rather than processing alone. Allow at least one full day of low-demand activity before returning to obligations.
Recovery & Support
5-MeO-AMT has low abuse liability and is not associated with compulsive use patterns. If use has become a pattern driven by avoidance, escapism, or compulsion rather than intentional exploration, this signals a relationship with the substance worth examining honestly.
Psychedelic-informed therapists, peer support communities, and integration circles can provide context and perspective. The Fireside Project (62-FIRESIDE / 623-473-7433) offers free peer support for people processing difficult psychedelic experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
Not every difficult moment requires medical intervention, but certain signs do:
- Seizures or convulsions
- Chest pain or irregular heartbeat
- Body temperature you can feel through clothing (dangerously elevated)
- Loss of consciousness or inability to respond
- Severe confusion with self-harm risk
- Rigid muscles with high fever (possible serotonin syndrome)
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present.
- 2. Place the person in the recovery position if unconscious but breathing.
- 3. Do not attempt to restrain someone having a seizure — clear the area of hard objects and protect the head.
- 4. Remove excess clothing and apply cool (not cold) water if body temperature is elevated.
- 5. Do not induce vomiting.
- 6. Stay with the person until help arrives.
What to tell the dispatcher:
State the substance name (5-MeO-AMT), approximate dose if known, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency — calling for help is always the right decision.
Legal Status[edit]
5-MeO-AMT occupies an unusual legal position among serotonergic tryptamines. It remains federally unscheduled in the United States — a status preserved when the DEA withdrew its proposed Schedule I placement in July 2022.[6] This contrasts with the structurally related αMT (Schedule I since 2003) and 5-MeO-DMT (Schedule I since 2011). In the United Kingdom and Australia, the compound is controlled under broad tryptamine scheduling provisions. Legal status varies by jurisdiction and should be verified against current legislation before any activity involving this substance.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (Federal) | Unscheduled | DEA proposed Schedule I placement January 14, 2022;[10] withdrawn July 27, 2022.[6] May be prosecutable under the Federal Analogue Act as an analogue of AMT or 5-MeO-DMT if intended for human consumption. |
| Florida (USA) | Schedule I | State-level scheduling; specifically listed. |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled from January 7, 2015 via updated generic tryptamine definition following ACMD recommendation. |
| Australia | Schedule 9 (Prohibited Substance) | Listed under the Poisons Standard.[8] |
| Sweden | Controlled (health hazard) | Classified under SFS 2004:696, Act on Prohibition of Certain Goods Dangerous to Health, from October 1, 2004. |
| Canada | Not specifically scheduled | Not explicitly listed in the Controlled Drugs and Substances Act. Potential analogue arguments may apply. |
The Federal Analogue Act (21 U.S.C. § 813) provides a potential enforcement mechanism in the United States, but its application requires demonstrating both structural similarity to a Schedule I or II substance and intent for human consumption, assessed case by case.
Frequently asked questions
What is 5-MeO-AMT?
5-MeO-AMT is a substituted tryptamine psychedelic active at low milligram doses, noted for extended duration (12-18 h) and a narrow therapeutic index. It combines potent 5-HT2A agonism with triple-monoamine reuptake inhibition and release, first characterized by Shulgin and Nichols in 1978.
How long does 5-MeO-AMT last?
Total duration by route of administration — Oral: 12 – 18 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for 5-MeO-AMT?
Psychedex publishes a dosage table for 5-MeO-AMT on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with 5-MeO-AMT?
The highest-severity documented interactions for 5-MeO-AMT: MAOIs (Lethal), 5-HTP, Tryptophan (Dangerous), Alpha-2 adrenergic receptor antagonist (Dangerous), Amphetamines (Dangerous), Antipsychotics (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is 5-MeO-AMT addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for 5-MeO-AMT: tolerance builds rapid; full reset takes 14 days; cross-tolerance develops with LSD, psilocybin, mescaline, DMT. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]